SecProbe.io

Mail Stop 3030

July 12, 2018

Via E -mail
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9640 Towne Centre Drive, Suite 100
San Diego, California 92121

Re: Bionano Genomics, Inc.
Registration Statement on Form S-1
Filed June 28, 2018
  File No. 333-225970

Dear Dr. Holmlin :

We have reviewed your registration statement  and have the following comments.  In
some of our comments, we may ask you to provide us with information so we may better
understand your disc losure.

Please respond to this letter by amending your registration statement and providing the
requested information .  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

After reviewing any amendment to your registration statement and the information you
provide in response to these  comments, we may have additional comments.

Overview, page 1

1. We note your response to prior comment 2.   Please revise to disclose the amount of
revenue received from each of the customers you mention.

Use of Proceeds, page 46

2. Please expand your response to prior comment 5 to clarify why you will be unable to
identify the amount to be used for each purpose disclosed.  Otherwise, revise to provide
the approximate amount intended to be used for each purpos e you disclose.  Refer to Item
504 of Regulation S -K.

R. Erik Holmlin, Ph.D.
Bionano Genomics, Inc.
July 12 , 2018
Page 2

 Results of Operations, page 56

3. It appears from your revision s in response to prior comment 7  that product volume
decreased for the period ended March 31, 2018.  If so, quantify and explain the reaso ns
for the decrease.

Government Regulation, page 84

4. We note your response to prior comment 3.  Please revise your disclosure to discuss the
regulatory requirements regarding laboratory developed tests and how these regulatory
requirements differ when the tests are developed wholly or partly outside of the
laboratory that offers them.  Also address in your disclosure whether you have pursued or
intend to pursue regulatory approval prior to sale to cytogenetics labs.

We remind you that the company an d its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

Refer to Rules 460 and 461 regarding requests for  acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.

You may contact Julie Sherman  at (202) 551 -3640 or Brian Cascio, Accounting Branch
Chief , at (202) 551 -3676 if you have questions regarding comments on the financial statements
and related matters.  Please contact Heather Percival  at (202) 551 -3498 or Geoff Kruczek, Senior
Attorney, at (202) 551 -3641 with any other questions.

Sincerely,

 /s/ Geoff Kruczek for

Amanda Ravitz
Assistant Director
Office of Electronics and Machinery

cc: James C. Pennington, Esq.
Cooley LLP